What We Do With Emerging SARS-CoV-2 Variants

Multiple SARS-CoV-2 variants are circulating globally. Several new variants emerged in the fall of 2020, most notably:

In the United Kingdom (UK), a new variant of SARS-CoV-2 (known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7) emerged with an unusually large number of mutations. This variant has a mutation in the receptor binding domain (RBD) of the spike protein at position 501, where amino acid asparagine (N) has been replaced with tyrosine (Y). The shorthand for this mutation is N501Y. This variant also has several other mutations, including 69/70 deletion and P681H.
In South Africa, another variant of SARS-CoV-2 (known as 20H/501Y.V2 or B.1.351) emerged independently of B.1.1.7. This variant has multiple mutations in the spike protein, including K417T, E484K, N501Y. Unlike the B.1.1.7 lineage detected in the UK this variant does not contain the deletion at 69/70. View More

Recombinant SARS-CoV-2 Spike Mutants

Creative Diagnostics has produced a collection of recombinant antigens for these variants. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

Cat. No.	Product Name	Source	Additional Information
DAGC488	Recombinant SARS-CoV-2 Spike S1 (HV69-70/Y144 deletion, N501Y, A570D, D614G, P681H) Protein [His]	HEK293 cells	variant 20I/501Y.V1, VOC 202012/01, or B.1.1.7
DAGC489	Recombinant SARS-CoV-2 Spike S1(K417N, E484K, N501Y, D614G) Protein [His]	HEK293 cells	variant 20H/501Y.V2 or B.1.351

Lentiviral SARS-CoV-2 Mutation Pseudovirus

Our team has been working diligently to stay abreast these new developments and are currently developing a serial of Lentiviral SARS-CoV-2 Mutation Pseudovirus.

Cat. No.	Product Name	Reporter Gene
COVL-B117	Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant B.1.1.7)	Luciferase
COVG-B117	Pseudotyped GFP rSARS-CoV-2 Spike (Variant B.1.1.7)	GFP
COVL-N439K	Pseudotyped Luciferase rSARS-CoV-2 Spike (N439K)	Luciferase
COVG-N439K	Pseudotyped GFP rSARS-CoV-2 Spike (N439K)	GFP
COVL-501YV2	Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant 501Y.V2)	Luciferase
COVG-501YV2	Pseudotyped GFP rSARS-CoV-2 Spike (Variant 501Y.V2)	GFP

SARS-CoV-2 Nucleoprotein Antibody Pair for Rapid COVID-19 Antigen Assays

CD anti-nucleoprotein antibodies expected to detect both UK and South African variants of SARS-CoV-2. The UK variant of SARS-CoV-2 (known as VOC 202012/01, lineage B.1.1.7, or 20B/501Y.V1) has two mutations in the nucleoprotein: D3L and S235F. We have validated that our key anti-NP clones NB1, NB2, and NJ1 are able to detect the UK variant. The South African variant of SARS-CoV-2 (known as 501.V2, 20C/501Y.V2 or B.1.351 lineage) does not have any mutations in its nucleoprotein and should be detected by all our anti-COVID-19 NP MAbs.

Cat. No.	Product Name	Source	Application
CABT-MMB1	Mouse Anti-SARS-CoV-2 NP monoclonal antibody, clone NB1	Mouse	Capture
CABT-MMB2	Mouse Anti-SARS-CoV-2 NP monoclonal antibody, clone NB2	Mouse	Detection
CABT-RMJ1	Rabbit anti-SARS-CoV-2 NP monoclonal antibody, clone NJ1	Rabbit	Detection

Best pairs in lateral flow：If you are developing a lateral flow -based test, we recommend you start with these two capture-detection pairs: CABT-MMB1-CABT-MMB2, CABT-MMB1-CABT-RMJ1.

New MAbs Available

We are pleased to let you know that we now have the first anti-nucleoprotein antibody (CABT-MMT2) which can not react with B.1.1.7 variant strain but react with other COVD-19 viral strains.

This antibody can be used for COVID-19 antigen lateral flow testing in differentiating Variant B.1.1.7 and other viral strains.